热休克蛋白gp96-肽复合物肿瘤疫苗的应用前景与挑战  

Future perspectives and challenges in the development of an antitumor vaccine based on heat shock protein gp96-peptide complex

作　　者：李常颖[1] 畅继武[1] 

机构地区：[1]天津医科大学第二医院、天津市泌尿外科研究所,天津市300211

出　　处：《中国肿瘤临床》2014年第11期738-740,共3页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金(编号:81301949);天津市科技支撑项目"抗癌重大专项"(编号:12ZCDZSY16500)资助~~

摘　　要：肿瘤组织来源的热休克蛋白gp96-肽复合物(heat shock protein 96-peptide complex,HSPPC-96)结合有肿瘤特异性抗原多肽,能够诱导特异性抗肿瘤免疫。自体HSPPC-96疫苗在延缓肿瘤复发和提高患者总体生存率等方面彰显优势,应用前景广阔。然而作为自体来源的个体化疫苗,HSPPC-96疫苗的实施和推广也面临着巨大的挑战,如肿瘤组织来源限制、对晚期肿瘤疗效不明确等问题。本文综合分析了HSPPC-96疫苗免疫治疗的临床进展、应用前景及其面临的挑战。Tumor-derived heat shock protein-peptide complex 96 （HSPPC-96） containing tumor antigenic peptides can elicit potent tumor-specific and protective immunity. Autologous HSPPC-96 vaccine has been shown to effectively prolong recurrence-free survival and increase the overall survival of many tumors, thereby suggesting extensive future applications. However, as an autologous tu-morderived individual vaccine, the development of HSPPC-96 vaccine is challenged by the lack of an adequate autologous tumor, lim-ited efficacy for advanced-stage cancer, etc. This paper summarized the progress, future perspectives, and challenges in the clinical development of HSPPC-96 vaccine immunotherapy.

关 键 词：GP96-肽复合物 肿瘤疫苗 免疫应答 应用前景 挑战 

分 类 号：R730.51[医药卫生—肿瘤]